[AME]Assessment and Treatment of Depression and Anxiety: Integrating Psychopharmacology and Psy...

[AME]Assessment and Treatment of Depression and Anxiety: Integrating Psychopharmacology and Psychotherapy 2021 (CME VIDEOS)
¥395.00 市场价 ¥899.99
库存
9999
数量
-
+
联系卖家   QQ:316821785   微信:zbook8_com  电话:13111111111   
商品特色:担保交易手动发货商品,工作人员手动发货。

自动发货宝贝:购买后直接到我买到的商品-订单详情-收货信息获取下载链接。
手动发货宝贝:购买后请留言邮箱或联系方式,0-4小时内由工作人员发到您邮箱。
购买后任何问题请联系商家或直接联系本站站务微信或者QQ。
书籍格式:
isbn:
排版:
新旧程度:

-------如果这里没有任何信息,不是真没有,是我们懒!请复制书名上amazon搜索书籍信息。-------

In addition to highlighting emerging strategies in the assessment and treatment of major depression and bipolar illness, this online CME course defines approaches to mood and anxiety disorders, including psychodynamic psychotherapy, cognitive and behavioral therapy, interpersonal psychotherapy for depression and other psychotherapeutic approaches.

Assessment and Treatment of Depression and Anxiety: Integrating Psychopharmacology and Psychotherapy also addresses comorbid conditions such as Axis II personality disorders, management of patients with medical conditions, management of the geriatric patient, and more. It’s psychiatry CME that offers insight into:

  • Issues around the choice of specific antidepressants, mood stabilizers and anti-anxiety medications
  • Psychopharmacologic management of the treatment resistant patient
  • Recent developments in neuropsychiatry, including brain imaging and therapeutic stimulation techniques
  • Therapeutic efficacy and risks associated with ketamine administration
  • Obsessive-compulsive disorders including skin-picking, trichotillomania and body dysmorphic
  • Management of anxiety in patients vulnerable to abuse of alcohol
  • And more…

Learning Objectives

Upon completion of this activity, participants will be better able to:

  • Evaluate emerging strategies in the use of psychotropic medications in the treatment of major depression and anxiety disorders and integrate psychopharmacologic treatments into psychotherapy strategies in treating depressed and anxious patents
  • Describe strategies for the psychopharmacological and psychotherapeutic management of treatment resistant depression
  • Summarize the emerging role of ketamine in the treatment of major depression and suicidal behavior
  • Explore the role of novel enhancements to treatment of mood disorders including omega 3 fatty acids, 1 methylfolate and zinc
  • Discuss the role of electroconvulsive therapy and Transcranial Magnetic Stimulation in treatment resistant depressive disorders
  • Examine new developments in the treatment of depression in bipolar patients with a focus on newer medications including lurasidone and cariprazine
  • Identify an evidence-based approach to suicide risk assessment and prevention of suicide
  • Appreciate the role of lithium carbonate in combination with other mood stabilizing agents
  • Give examples of recent developments in psychotherapeutic approaches to treating Bipolar patients, including cognitive, behavioral and expressive psychotherapy techniques
  • Integrate psychodynamic assessment, psychotherapy and psychopharmacology into management of depression and anxiety disorders
  • Assess the role of Cognitive Behavioral Therapy (CBT) in the treatment of depression and anxiety disorders
  • Compare recent developments in the implementation of CBT, including Commitment and Acceptance Therapy and inclusion of exposure therapy in CBT
  • Report on the latest applications for computer- based treatment of OCD and other anxiety disorders
  • Describe new psychopharmacological and psychotherapeutic techniques in the treatment of PTSD including exposure and response prevention and virtual reality techniques utilized to treat PTSD secondary to exposure to combat
  • Formulate an integrated psychopharmacological and psychotherapeutic approach to personality-disordered patients in the borderline and severely narcissistic spectrum presenting with depression and anxiety
  • Manage anxiety disorders in patients vulnerable to alcohol abuse and psychological dependence on marijuana, including the use of non-benzodiazepine anti-anxiety agents such as pregabalin and buspirone
  • Formulate strategies for treating patients with marijuana abuse disorder, including discussion of newly emerging psychopharmacological and psychotherapeutic techniques

Target Audience

This educational activity was designed for health professionals in the fields of psychiatry, psychology, nursing, social work, counseling, medicine, pediatrics, and surgery.

TOPICS / SPEAKERS

All lectures by Russell G. Vasile, MD

Assessment and Treatment of Major Depressive Disorder

Psychopharmacologic Management of Bipolar Disorder Emerging Perspectives

Anxiety Disorders- Assessment and Pharmacotherapy

Suicide Assessment and Prevention, Psychotherapy of Depression and Perspectives on Personality Disorder

Assessment and Management of Depression in the Elderly and Brain Imaging

Date of Original Release: October 15, 2021

Termination Date: January 31, 2024

Estimated Time to Complete the Activity: 13.00 hours


暂无评价
暂时没有数据

交易规则

免责声明


1、本站所有分享材料(数据、资料)均为网友上传,如有侵犯您的任何权利,请您第一时间通过微信(zbook8_com) 、QQ(316821785)、 电话(13111111111)联系本站,本站将在24小时内回复您的诉求!谢谢!
2、本站所有商品,除特殊说明外,均为(电子版)Ebook,请购买分享内容前请务必注意。特殊商品有说明实物的,按照说明为准。

发货方式


1、自动:在上方保障服务中标有自动发货的宝贝,拍下后,将会自动收到来自卖家的宝贝获取(下载)链接   [个人中心->我的订单->点击订单 查看详情];
2、手动:未标有自动发货的的宝贝,拍下后,通过QQ或订单中的电话联系对方。

退款说明


1、描述:书籍描述(含标题)与实际不一致的(例:描述PDF,实际为epub、缺页少页、版本不符等);
2、链接:部分图书会给出链接,直接链接到官网或者其他站点,以便于提示,如与给出不符等;
3、发货:手动发货书籍,在卖家未发货前,已申请退款的;
4、其他:如质量方面的硬性常规问题等。
注:经核实符合上述任一,均支持退款,但卖家予以积极解决问题则除外。交易中的商品,卖家无法对描述进行修改!

注意事项


1、在未购买下前,双方在QQ上所商定的内容,亦可成为纠纷评判依据(商定与描述冲突时,商定为准);
2、在宝贝同时有网站演示与图片演示,且站演与图演不一致时,默认按图演作为纠纷评判依据(特别声明或有商定除外);
3、在没有"无任何正当退款依据"的前提下,写有"一旦售出,概不支持退款"等类似的声明,视为无效声明;
4、虽然交易产生纠纷的几率很小,但请尽量保留如聊天记录这样的重要信息,以防产生纠纷时便于网站工作人员介入快速处理。